Vanguard Global Advisers’s Viridian Therapeutics VRDN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$906K Buy
43,981
+3,231
+8% +$69K ﹤0.01% 1772
2026
Q2
$749K Buy
40,750
+5,425
+15% +$87.4K ﹤0.01% 1919
2026
Q1
$691K Buy
+35,325
New +$1.05M ﹤0.01% 1874

Other funds holding VRDN

Vanguard Global Advisers's VRDN Position: Q3 2026 in Review

Vanguard Global Advisers increased its Viridian Therapeutics (VRDN) stake by 7.9% in Q3 2026, buying an estimated $69K and bringing the position to 43,981 shares worth $906K. The position accounts for ﹤0.01% of the portfolio, ranked #1772.

Vanguard Global Advisers first reported a position in VRDN in Q1 2026 and has held it in 3 quarters since. 235 funds tracked by Wall St. Rank hold VRDN as of Q3 2026.

  • Vanguard Global Advisers held 43,981 shares of Viridian Therapeutics worth $906K as of Q3 2026.
  • Vanguard Global Advisers bought 3,231 Viridian Therapeutics shares in Q3 2026, an estimated $69K.
  • Viridian Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #1772 holding.
  • Vanguard Global Advisers first reported a position in Viridian Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 235 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2026.

Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.